For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant advancement . These innovative therapies preserve the transthyretin protein, halting its harmful build-up and alleviating the severity of the illness. Individuals are now seeing